Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Newron Pharmaceuticals SpA ( (CH:NWRN) ) has provided an announcement.
Newron Pharmaceuticals reported a transformative 2025 marked by major advances in its Evenamide program, including regulatory approval and global initiation of the ENIGMA-TRS Phase III trials for treatment-resistant schizophrenia, expanded intellectual property protection to 2044, and publication of supportive clinical data in leading journals. The company also saw leadership changes on its board, strengthened its balance sheet through new equity financing and extended EIB debt maturities, and, despite a swing to a net loss on lower licensing income versus 2024, ended the year with higher cash and a funding runway expected to support operations and key development programs well into 2027 as pivotal trial readouts approach.
The most recent analyst rating on (CH:NWRN) stock is a Hold with a CHF21.50 price target. To see the full list of analyst forecasts on Newron Pharmaceuticals SpA stock, see the CH:NWRN Stock Forecast page.
More about Newron Pharmaceuticals SpA
Newron Pharmaceuticals is a biopharmaceutical company focused on developing novel therapies for central and peripheral nervous system disorders. Headquartered near Milan, it has experience taking neuroscience-based drugs from discovery to market, and its lead candidate Evenamide targets treatment-resistant schizophrenia as a first-in-class glutamate modulator now in a global Phase III program.
Average Trading Volume: 146,194
Technical Sentiment Signal: Buy
Current Market Cap: CHF311.4M
See more data about NWRN stock on TipRanks’ Stock Analysis page.